Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Christina Canil"'
Autor:
Eric K. Nguyen, MD, Aly Khan A. Lalani, MD, Sunita Ghosh, PhD, PStat, Naveen S. Basappa, MD, Anil Kapoor, MD, Aaron R. Hansen, MD, Christian Kollmannsberger, MD, Daniel Heng, MD, MPH, Lori A. Wood, MD, MSc, Vincent Castonguay, MD, Denis Soulières, MD, MSc, Eric Winquist, MD, MSc, Christina Canil, MD, Jeffrey Graham, MD, Georg A. Bjarnason, MD, Rodney H. Breau, MD, MSc, Frédéric Pouliot, MD, PhD, Anand Swaminath, MD, MSc
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 4, Pp 100899- (2022)
Purpose: With the integration of immunotherapy (IO) agents in the management of metastatic renal cell carcinoma (mRCC), there has been interest in the combined use with radiation therapy (RT). However, real world data are limited. The purpose of this
Externí odkaz:
https://doaj.org/article/43f035c672774db193ffcf1e0e1b7f1a
Autor:
Laura Burgess, Marissa Keenan, Alan Liang Zhou, Kiefer Lypka, Delvina Hasimja Saraqini, Jeff Yao, Samuel Martin, Christopher Morash, James Watterson, Christina Canil, Robert MacRae
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 1744-1750 (2021)
Approximately 20% of renal cell carcinoma (RCC) is diagnosed because of paraneoplastic manifestations. RCC has been associated with a large variety of paraneoplastic syndromes (PNS), but it is rarely associated with PNS vasculitis. We present a case
Externí odkaz:
https://doaj.org/article/1b1f85348c4e496991215269984e769e
Autor:
Greg Knoll, Michael Ong, Andrea Marie Ibrahim, Samuel Bourassa-Blanchette, Christina Canil, Todd Fairhead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have gen
Externí odkaz:
https://doaj.org/article/4eb72c8aff494b408e58dcc1074c8318
Autor:
Bimal Bhindi, Simon Tanguay, Frédéric Pouliot, Christina Canil, Sebastien J. Hotte, Alan I. So, Alice Dragomir, Daniel Heng, Rodney H. Breau, Nicholas Power, Jean-Baptiste Lattouf, Sara Nazha, Aaron R. Hansen, Ricardo A. Rendon, Antonio Finelli, Adrian Fairey, Lori Wood, Christian K. Kollmannsberger, Georg A. Bjarnason, Naveen S. Basappa, Anil Kapoor
Publikováno v:
European Urology Focus. 8:1703-1710
Background Treatment options for metastatic renal cell carcinoma (mRCC) include cytoreductive nephrectomy (CN) and systemic therapy (ST). Results from the CARMENA and SURTIME trials suggest that CN before ST may not be the optimal treatment strategy
Autor:
Ryan, Flannigan, Andrew, Matthew, Sydney, Sparanese, Eugenia, Wu, Steven, Guirguis, Monita, Sundar, Fred, Saad, Andrew, Loblaw, Jessica, Nargi, Luke, Witherspoon, Christina, Canil, Ricardo A, Rendon, Laura, Labelle, Jill, Turner, Celestia, Higano
Publikováno v:
Can Urol Assoc J
Autor:
Noa Shani Shrem, Lori Wood, Robert J. Hamilton, Kopika Kuhathaas, Piotr Czaykowski, Matthew Roberts, Andrew Matthew, Jason Izard, Peter Chung, Lucia Nappi, Jennifer Jones, Denis Soulières, Armen Aprikian, Nicholas Power, Christina Canil
Publikováno v:
Can Urol Assoc J
Autor:
Alan Liang Zhou, Delvina Hasimja Saraqini, James Watterson, Laura Burgess, Christopher Morash, Jeff Yao, Samuel Martin, Kiefer Lypka, Robert MacRae, Marissa Keenan, Christina Canil
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 162, Pp 1744-1750 (2021)
Current Oncology, Vol 28, Iss 162, Pp 1744-1750 (2021)
Approximately 20% of renal cell carcinoma (RCC) is diagnosed because of paraneoplastic manifestations. RCC has been associated with a large variety of paraneoplastic syndromes (PNS), but it is rarely associated with PNS vasculitis. We present a case
Autor:
Sandeep Sehdev, Brian Hutton, Lisa Vandermeer, Christina Canil, Arif Awan, Mark Clemons, Noa Shani Shrem, Marta Sienkiewicz, Sharon F. McGee, Terry L. Ng, Deanna Saunders, Gregory R. Pond, Mashari Alzahrani
Publikováno v:
Supportive Care in Cancer
Background Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving. Methods Patients receiving BMA for bone metastases from breast or CRPC were surveyed.
Publikováno v:
Surgical Oncology Clinics of North America. 30:89-102
Genitourinary cancers are common. Liver metastases from genitourinary cancers are uncommon; isolated liver metastasis is rare. Liver resection in select patients with metastatic renal cell carcinoma can lead to prolonged survival. Patients with metac
Autor:
Mary Mahler, Esmail Al-Ezzi, Noa Shani Shrem, Liying Zhang, Eric Winquist, Christina Canil, Michael Ong, Aaron R. Hansen, Urban Emmenegger
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 40:539.e17-539.e22
To assess the effectiveness of docetaxel rechallenge (DR) for metastatic castration-resistant prostate cancer (mCRPC) following chemohormonal therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Additionally, we sought to define clinica